Verapamil P-glycoprotein Transport across the Rat Blood-Brain Barrier: Cyclosporine, a Concentration Inhibition Analysis, and Comparison with Human Data

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2006-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.105.097931PMID 16415090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.

  2005cited by this paper
• Imaging P‐glycoprotein Transport Activity at the Human Blood‐brain Barrier with Positron Emission Tomography

  2005cited by this paper
• Chronic cyclosporine nephrotoxicity: new insights and preventive strategies.

  2004cited by this paper
• The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice

  2004cited by this paper
• Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

  2004cited by this paper
• Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET

  2003cited by this paper
• (R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation.

  2003cited by this paper
• Blood-brain barrier efflux transport.

  2003influential reference
• Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

  2003cited by this paper
• Functional expression and localization of P‐glycoprotein at the blood brain barrier

  2002influential reference
• Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier.

  2002influential reference
• Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.

  2000cited by this paper
• The blood-brain barrier and oncology: new insights into function and modulation.

  2000influential reference
• Complete in vivo reversal of P‐glycoprotein pump function in the blood‐brain barrier visualized with positron emission tomography

  1998cited by this paper
• Long-term improvement in renal function after cyclosporine reduction in renal transplant recipients with histologically proven chronic cyclosporine nephropathy.

  1998cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• PHARMACOKINETICS OF THE ENANTIOMERS OF VERAPAMIL AFTER INTRAVENOUS AND ORAL ADMINISTRATION OF RACEMIC VERAPAMIL IN A RAT MODEL

  1997cited by this paper
• P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier.

  1997cited by this paper
• Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

  1997cited by this paper
• Physiological Parameter Values for Physiologically Based Pharmacokinetic Models

  1997cited by this paper
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

  1996cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Regiochemistry and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver.

  1988cited by this paper
• Methods for Quantifying the transport of drugs across brain barrier systems.

  1981cited by this paper

• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• Mechanisms and implications in gene polymorphism mediated diverse reponses to sedatives, analgesics and muscle relaxants

  2022cites this paper
• Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats

  2021cites this paper
• Transporter-mediated drug–drug interactions: advancement in models, analytical tools, and regulatory perspective

  2021cites this paper
• HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model

  2020cites this paper
• Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood–brain barrier

  2020cites this paper
• Role of P-glycoprotein in the brain disposition of seletalisib: Evaluation of the potential for drug-drug interactions.

  2020cites this paper
• Mechanisms and the clinical relevance of complex drug–drug interactions

  2018cites this paper
• Imaging techniques to study drug transporter function in vivo.

  2018cites this paper
• Critical Issues and Optimized Practices in Quantification of Protein Abundance Level to Determine Interindividual Variability in DMET Proteins by LC‐MS/MS Proteomics

  2018cites this paper
• In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain

  2018cites this paper
• Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans

  2018cites this paper
• IPEC-J2 MDR1, a Novel High-Resistance Cell Line with Functional Expression of Human P-glycoprotein (ABCB1) for Drug Screening Studies.

  2016cites this paper
• Stem Cell-Based Human Blood-Brain Barrier Models for Drug Discovery and Delivery.

  2016cites this paper
• Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain

  2016cites this paper
• Blood-brain barrier permeability of ginkgolide: Comparison of the behavior of PET probes 7α-[18F]fluoro- and 10-O-p-[11C]methylbenzyl ginkgolide B in monkey and rat brains.

  2016cites this paper
• 溶媒抽出表面分析法（LESA: Liquid Extraction Surface Analysis）を用いたイメージング質量分析

  2016cites this paper
• Use of PET Imaging to Evaluate Transporter‐Mediated Drug‐Drug Interactions

  2016cites this paper
• Combined Hydroxyurea and Verapamil in the Clinical Treatment of Refractory Meningioma: Human and Orthotopic Xenograft Studies.

  2016cites this paper
• Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design.

  2016cites this paper
• Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment : a PET Imaging Study

  2015cites this paper
• CNS drug design: balancing physicochemical properties for optimal brain exposure.

  2015cites this paper
• Factors Governing P-Glycoprotein-Mediated Drug–Drug Interactions at the Blood–Brain Barrier Measured with Positron Emission Tomography

  2015cites this paper
• Cyclosporine A kinetics in brain cell cultures and its potential of crossing the blood-brain barrier.

  2015cites this paper
• Oestrogen enhances cardiotoxicity induced by Sunitinib by regulation of drug transport and metabolism.

  2015cites this paper
• Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB)

  2015cites this paper
• Species Differences and Impact of Disease State on BBB

  2015cites this paper
• Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study

  2015cites this paper
• Predicting the outer boundaries of P-glycoprotein (P-gp)-based drug interactions at the human blood-brain barrier based on rat studies.

  2014cites this paper
• Cyclosporine-inhibitable Cerebral Drug Transport Does Not Influence Clinical Methadone Pharmacodynamics

  2014cites this paper
• Influence of active efflux transport on the distribution of targeted agents to brain tumors

  2014cites this paper
• Impact of ABC transporters on secondary fungal metabolites as remedies or toxins

  2014cites this paper
• Confounding parameters in preclinical assessment of blood-brain barrier permeation: an overview with emphasis on species differences and effect of disease states.

  2013cites this paper
• Predicting Drug Disposition during Pregnancy through Modeling and Simulation

  2013cites this paper
• Species differences in drug transporters and implications for translating preclinical findings to humans

  2013cites this paper
• Sucralose, A Synthetic Organochlorine Sweetener: Overview of Biological Issues

  2013cites this paper
• Immunosuppressive drugs, immunophilins, and functional expression of NCX isoforms.

  2013cites this paper
• Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset.

  2013cites this paper
• The Use of Microdialysis Techniques in Mice to Study P-gp Function at the Blood-Brain Barrier

  2013cites this paper
• Modeling Cyclosporine A Inhibition of the Distribution of a P-Glycoprotein PET Ligand, 11C-Verapamil, into the Maternal Brain and Fetal Liver of the Pregnant Nonhuman Primate: Impact of Tissue Blood Flow and Site of Inhibition

  2013cites this paper
• Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach

  2013cites this paper
• Cyclosporine-inhibitable Blood–Brain Barrier Drug Transport Influences Clinical Morphine Pharmacodynamics

  2013cites this paper
• Enzyme and transporter-mediated drug-drug and herb-drug interactions of the antimalarials and HIV antiretrovirals

  2013cites this paper
• Transporter study methodologies

  2013cites this paper
• Pgp‐Mediated Interaction Between (R)‐[11C]Verapamil and Tariquidar at the Human Blood–Brain Barrier: A Comparison With Rat Data

  2012cites this paper
• Utility of Genetically Modified Animal Models for Drug Metabolism and Drug Transporters

  2012cites this paper
• Models to Predict Unbound Intracellular Drug Concentrations in the Presence of Transporters

  2012cites this paper
• The involvement of a Na⁺- and Cl⁻-dependent transporter in the brain uptake of amantadine and rimantadine.

  2012cites this paper
• P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans.

  2012cites this paper
• Effects of Electromagnetic Fields From Wireless Communication upon the Blood-Brain Barrier

  2012cites this paper
• Effects of borneol on the intestinal transport and absorption of two P-glycoprotein substrates in rats

  2011cites this paper
• Assessing p-Glycoprotein (Pgp) Activity In Vivo Utilizing 68Ga–Schiff Base Complexes

  2011cites this paper
• Substrate- and species-dependent inhibition of P-glycoprotein-mediated transport: implications for predicting in vivo drug interactions.

  2011cites this paper
• Quantitative Investigation of the Impact of P-Glycoprotein Inhibition on Drug Transport across Blood-Brain Barrier in Rats

  2011cites this paper
• Exposure of LS-180 cells to drugs of diverse physicochemical and therapeutic properties up-regulates P-glycoprotein expression and activity.

  2011cites this paper
• Nasal delivery of P-gp substrates to the brain through the nose-brain pathway.

  2011cites this paper
• Liquid chromatography/tandem mass spectrometry based targeted proteomics quantification of P-glycoprotein in various biological samples.

  2011cites this paper
• Effect of Verapamil on Serum Level of Salinomycin in Diabetic Rats

  2011cites this paper
• Automated radiosynthesis of [11C]morphine for clinical investigation.

  2011cites this paper
• The Impact and In Vitro to In Vivo Prediction of Transporter-Based Drug–Drug Interactions in Humans

  2010cites this paper
• P-glycoprotein related drug interactions: clinical importance and a consideration of disease states

  2010cites this paper
• Regional P‐Glycoprotein Activity and Inhibition at the Human Blood–Brain Barrier as Imaged by Positron Emission Tomography

  2010cites this paper
• Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs.

  2010cites this paper
• Active-site concentrations of chemicals - are they a better predictor of effect than plasma/organ/tissue concentrations?

  2010cites this paper
• Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress

  2010cites this paper
• Positron emission tomography imaging of tissue P‐glycoprotein activity during pregnancy in the non‐human primate

  2010influential citation
• Species Differences in Blood-Brain Barrier Transport of Three Positron Emission Tomography Radioligands with Emphasis on P-Glycoprotein Transport

  2009cites this paper
• Methodologies to assess brain drug delivery in lead optimization.

  2009cites this paper
• ABC transporters and isothiocyanates: potential for pharmacokinetic diet-drug interactions.

  2009cites this paper
• Simultaneous PET Imaging of P-Glycoprotein Inhibition in Multiple Tissues in the Pregnant Nonhuman Primate

  2009cites this paper
• Invited Speaker Abstracts

  2009cites this paper
• Drug interactions at the blood-brain barrier: fact or fantasy?

  2009cites this paper
• Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein

  2008cites this paper
• Rapid solid-phase extraction method to quantify [(11)C]-verapamil, and its [(11)C]-metabolites, in human and macaque plasma.

  2008cites this paper
• Pharmacokinetics and brain uptake of AM‐36, a novel neuroprotective agent, following intravenous administration to rats

  2008cites this paper
• Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies

  2008cites this paper
• Modulation of Na+-Ca2+ Exchanger Expression by Immunosuppressive Drugs Is Isoform-Specific

  2008cites this paper
• Species differences in blood-brain barrier transport of three PET radioligands with emphasis on P-glycoprotein transport

  2008influential citation
• Identification of interspecies difference in efflux transporters of hepatocytes from dog, rat, monkey and human.

  2008cites this paper
• Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.

  2008cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 70 Blood-Brain Barrier Transport Investigation of Active Efflux using Positron Emission Tomography and Modelling Studies

  2008cites this paper
• Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier.

  2008cites this paper
• Progress in Brain Penetration Evaluation in Drug Discovery and Development

  2008influential citation
• Progress in Brain Penetration Evaluation in Drug Discovery and Development

  2008influential citation
• Molecular Imaging of Transporters with Positron Emission Tomography

  2008cites this paper
• Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia

  2008cites this paper
• Role of transport proteins in drug discovery and development: a pharmaceutical perspective

  2008cites this paper
• MODULATION OF NCX (Na + -Ca 2+ EXCHANGER) EXPRESSION BY

  2008cites this paper
• In Vitro-to-in Vivo Prediction of P-glycoprotein-Based Drug Interactions at the Human and Rodent Blood-Brain Barrier

  2008cites this paper
• Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition

  2008cites this paper
• Role of transport proteins in drug discovery and development: a pharmaceutical perspective.

  2008cites this paper
• Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PET

  2008cites this paper
• Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients

  2007cites this paper
• On The Rate and Extent of Drug Delivery to the Brain

  2007cites this paper
• Genetic Polymorphisms in the ABCB1 Gene and the Effects of Fentanyl in Koreans

  2007cites this paper
• Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development

  2007cites this paper
• Reply

  2006cites this paper
• Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.

  2006cites this paper
• Interações Medicamentosas P-glycoprotein role on drug pharmacokinetics and interactions

  year unknowncites this paper
• Special Section – New Models in Drug Metabolism and Transport Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans s

  year unknowncites this paper